Vivos Therapeutics’ proprietary Vivos System(R) leverages a multidisciplinary treatment protocol comprised of comfortable oral devices and other therapies as needed. Over the course of treatment, typically ranging from 18 to 24 months, most patients experience an increased and enhanced upper airway with the purpose of reducing tissue obstructions causing obstructive sleep apnea (“OSA”). A recent article discussing this reads, “Vivos Therapeutics Inc. offers a new and superior alternative for treating obstructive sleep apnea, and the company believes its technology represents the most important breakthrough in OSA treatment since Continuous Positive Airway Pressure (‘CPAP’), which involves the use of special face or nasal masks.”
To view the full article, visit http://ibn.fm/yk92W
About Vivos Therapeutics Inc.
Vivos Therapeutics is an emerging global leader in the treatment of obstructive sleep apnea (“OSA”), a debilitating condition affecting nearly 1 billion people worldwide. Headquartered in Denver, Colorado, the company utilizes proprietary, groundbreaking technology; a proven, go-to-market strategy; and a powerful executive team dedicated to changing the face of health care by helping people of all ages properly breathe and sleep. At the core of Vivos’ mission to eradicate OSA is the Vivos System(R), a revolutionary clinical breakthrough in the treatment of sleep apnea caused by craniofacial anatomy development. The Vivos System multidisciplinary treatment protocol involves collaboration between physicians, specially trained dentists who have completed advanced training in craniofacial sleep medicine, and other ancillary health-care providers. In support of its growth strategy, Vivos has established FDA-approved and registered manufacturing facilities in the United States, Canada and Asia. For more information, visit the company’s website at www.VivosLife.com.
NOTE TO INVESTORS: The latest news and updates relating to Vivos Therapeutics are available in the company’s newsroom at http://ibn.fm/VVOS
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
